Please assess the completion status of the following clinical trial:

Trial Title: Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* no response or \< 25% reduction in subjective nocturia by the IPSS question 7 after 4-weeks of treatment with terazosin~* no response or \< 25% reduction in objective nocturia by the FVC after 4-weeks of treatment with terazosin~* nocturia on average two times or more per night (according to the FVC) after 4-weeks of terazosin therapy~Exclusion Criteria:~* use of medications for the control of bladder symptoms~* use of sedatives or tranquillisers for treating sleep disturbances~* bladder tumours~* bladder stones~* urethral strictures~* neurogenic bladder dysfunction~* restricted mobility~* working primarily at night~* a documented history or clinical symptoms of prostatitis, prostate cancer, or prostatic intraepithelial neoplasia on biopsy~* serum PSA levels of \>20 ng/mL~* a history of prostate surgery or radiotherapy, acute urinary retention or an indwelling catheter~* evidence of acute urinary infection (pyuria and bacteriuria)on urine analysis

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).